ACP-104: Completed Phase IIb enrollment

ACAD completed enrollment of 248 patients experiencing an acute psychotic episode in a double-blind Phase IIb trial comparing 100 mg and 200 mg of oral ACP-104 given twice daily vs. placebo for 6 week...